Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New combo therapy shows promise for inoperable liver cancer

NCT ID NCT06040099

First seen Nov 06, 2025 · Last updated May 24, 2026 · Updated 23 times

Summary

This study is for people with a type of liver cancer that cannot be removed by surgery. It tests a treatment plan that starts with a targeted radiation procedure (TARE) using tiny glass beads, followed by two drugs (durvalumab and bevacizumab) that help the immune system fight the cancer. The goal is to see if this combination can slow or stop the cancer from growing. About 58 participants are taking part in this phase 2 trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Research Site

    Aurora, Colorado, 80045, United States

  • Research Site

    Gainesville, Florida, 32608, United States

  • Research Site

    Orlando, Florida, 32804, United States

  • Research Site

    Atlanta, Georgia, 30322, United States

  • Research Site

    Atlanta, Georgia, 30342, United States

  • Research Site

    Chicago, Illinois, 60611, United States

  • Research Site

    Boston, Massachusetts, 02118, United States

  • Research Site

    Detroit, Michigan, 48201, United States

  • Research Site

    St Louis, Missouri, 63110, United States

  • Research Site

    Trenton, New Jersey, 08690, United States

  • Research Site

    Buffalo, New York, 14263, United States

  • Research Site

    New York, New York, 10029, United States

  • Research Site

    Chapel Hill, North Carolina, 27599, United States

  • Research Site

    Columbus, Ohio, 43210, United States

  • Research Site

    Portland, Oregon, 97239, United States

  • Research Site

    Philadelphia, Pennsylvania, 19107, United States

  • Research Site

    Houston, Texas, 77030, United States

  • Research Site

    Charlottesville, Virginia, 22908, United States

  • Research Site

    Seattle, Washington, 98195, United States

  • Research Site

    Milwaukee, Wisconsin, 53215, United States

  • Research Site

    Milwaukee, Wisconsin, 53226, United States

Conditions

Explore the condition pages connected to this study.